The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2022 | Targeting cold tumors with anti-PVRIG immunotherapy
Poliovirus receptor-related immunoglobulin domain-containing (PVRIG) is a novel immune checkpoint receptor predominantly expressed in stem-like memory T cells. Eran Ophir, PhD, Compugen Ltd., Tel Aviv, Israel, comments on targeting PVRIG with immunotherapies in immunologically cold tumors. Stem-like memory T cells are mainly localized in the tumor microenvironment and preliminary data assessing COM701 in solid tumors including microsatellite stable colorectal cancer have shown PVRIG to be a promising target. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
